Market research
MRK.F MERCK Kommanditgesellschaft auf Aktien
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 57B
- P/E ratio
- 23.85
- Analyst target
- 154.2143
- Dividend yield
- 1.7%
- Beta
- 0.81
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- DE0006599905
- Market cap
- 57B
- P/E ratio
- 23.85
- Analyst target
- 154.2143
- Dividend yield
- 1.7%
- Beta
- 0.81
About
About MERCK Kommanditgesellschaft auf Aktien
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor; and strategic partnership with Versant Ventures to advance treatments for rare genetic cardiomyopathies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a sub
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MRK.F discussion.
5 years, 5 months ago
MERCK Kommanditgesellschaft auf Aktien is currently in a long term uptrend where the price is trading 20.6% above its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.6.
MERCK Kommanditgesellschaft auf Aktien's total revenue rose by 5.0% to $5B since the same quarter in the previous year.
Its net income has increased by 37.1% to $436M since the same quarter in the previous year.
Finally, its free cash flow grew by 82.6% to $652M since the same quarter in the previous year.
Based on the above factors, MERCK Kommanditgesellschaft auf Aktien gets an overall score of 5/5.